{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:07:50Z","timestamp":1768014470034,"version":"3.49.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Today, many medical interventions that begin as treatments for disease often expand into therapies that reduce disability, lessen disadvantage, or even confer advantage. Forces that propel profitable drugs, devices, and procedures dominate over considerations of efficient and equitable distribution of resources. This dominance is fueled by industry-physician collaborations often biased by prior assumptions, reliant on surrogate outcomes, and advantageous to marketing. Interventions are justified by \u201cmedicalization\u201d of physiologic variations (e.g. short stature) as defects or disease, and nudged into \u201cstandard practice\u201d by key opinion leaders. The story below of recombinant human growth hormone (hGH) treatment of short stature is one vivid example, but others (e.g. expansion of drug treatment to \u201coptimize\u201d cholesterol profiles, bone health, psychological well-being) can be found throughout medicine. In the new obesity era, lessons learned from the hGH era will be needed to keep the field of pediatric endocrinology empowered to make the key clinical decisions, and free of unintended consequences for patients and runaway health care inflation for society.<\/jats:p>","DOI":"10.1210\/jc.2011-1739","type":"journal-article","created":{"date-parts":[[2011,8,25]],"date-time":"2011-08-25T03:34:08Z","timestamp":1314243248000},"page":"3042-3047","source":"Crossref","is-referenced-by-count":21,"title":["Lessons Learned from the hGH Era"],"prefix":"10.1210","volume":"96","author":[{"given":"David B.","family":"Allen","sequence":"first","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071616571328800_B1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0140-6736(10)60185-7","article-title":"Too tall, too small? The temptation to tinker with a child's height.","volume":"375","author":"Cohen","year":"2010","journal-title":"Lancet"},{"key":"2020071616571328800_B2","article-title":"The people's history of the United States","author":"Zinn","year":"1980"},{"key":"2020071616571328800_B3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM198509193131207","article-title":"Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone.","volume":"313","author":"Gibbs","year":"1985","journal-title":"N Engl J Med"},{"key":"2020071616571328800_B4","first-page":"2298","article-title":"The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment.","volume":"80","author":"Hintz","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1210\/jcem.82.2.3726","article-title":"Growth hormone retesting and auxological data of 131 GH-deficient patients after completion of treatment.","volume":"82","author":"Tauber","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1210\/jcem.84.4.5614","article-title":"Growth hormone deficiency of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults.","volume":"84","author":"Maghnie","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1203\/00006450-200011000-00003","article-title":"Growth hormone testing and the short child.","volume":"48","author":"Guyda","year":"2000","journal-title":"Pediatr Res"},{"key":"2020071616571328800_B8","first-page":"46","article-title":"Growth hormone therapy for short stature: can we support the treatment enhancement distinction?","volume":"8","author":"Daniels","year":"1992","journal-title":"Growth Genet Horm"},{"key":"2020071616571328800_B9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jama.1989.03420070070033","article-title":"Ethical issues in growth hormone therapy.","volume":"261","author":"Lantos","year":"1989","journal-title":"JAMA"},{"key":"2020071616571328800_B10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(05)82438-2","article-title":"Growth hormone for short stature: panacea or Pandora's box?","volume":"117","author":"Allen","year":"1990","journal-title":"J Pediatr"},{"key":"2020071616571328800_B11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-3476(05)81883-9","article-title":"Growth hormone and normal short children.","volume":"118","author":"Moshang","year":"1991","journal-title":"J Pediatr"},{"key":"2020071616571328800_B12","first-page":"78S","article-title":"Growth hormone: a paradigm of expansive biotechnologies.","volume":"11","author":"Buchanan","year":"2001","journal-title":"Endocrinologist"},{"key":"2020071616571328800_B13","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1530\/eje.0.151s055","article-title":"Lessons from the National Cooperative Growth Study.","volume":"151","author":"Wyatt","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071616571328800_B14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/jc.2009-2364","article-title":"Growth hormone post-marketing surveillance: safety, sales, and the unfinished task ahead.","volume":"95","author":"Allen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B15","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1210\/jc.2004-2513","article-title":"Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature.","volume":"90","author":"Kemp","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2265.2009.03775.x","article-title":"A continuum of GH-IGF axis defects causing short stature: diagnostic and therapeutic challenges.","volume":"72","author":"Savage","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616571328800_B17","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1542\/peds.94.6.832","article-title":"Short stature: a psychosocial burden requiring growth hormone therapy?","volume":"94","author":"Sandberg","year":"1994","journal-title":"Pediatrics"},{"key":"2020071616571328800_B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/adc.2002.010694","article-title":"Personality functioning: the influence of stature.","volume":"89","author":"Ulph","year":"2004","journal-title":"Arch Dis Child"},{"key":"2020071616571328800_B19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1542\/peds.2003-1169-L","article-title":"Height and social adjustment: are extremes a cause for concern and action.","volume":"114","author":"Sandberg","year":"2004","journal-title":"Pediatrics"},{"key":"2020071616571328800_B20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1542\/peds.2008-0085","article-title":"Short stature in a population-based cohort: social, emotional, and behavioral functioning.","volume":"124","author":"Lee","year":"2009","journal-title":"Pediatrics"},{"key":"2020071616571328800_B21","first-page":"439","article-title":"We are too tall.","volume":"12","author":"Samaras","year":"2009","journal-title":"Public Health Nutr"},{"key":"2020071616571328800_B22","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2003-031457","article-title":"Effect of GH treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, controlled trial.","volume":"89","author":"Leschek","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2004.08.055","article-title":"Growth hormone treatment to adult height in children with idiopathic short stature: evidence for a dose effect.","volume":"146","author":"Wit","year":"2005","journal-title":"J Pediatr"},{"key":"2020071616571328800_B24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000139150","article-title":"A randomized study of the effect of two doses of biosynthetic hGH on final height of children with familial short stature.","volume":"70","author":"Elder","year":"2008","journal-title":"Horm Res"},{"key":"2020071616571328800_B25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/archpedi.156.3.230","article-title":"Effect of GH therapy on height in children with idiopathic short stature: a meta-analysis.","volume":"156","author":"Finkelstein","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2020071616571328800_B26","first-page":"CD004440","article-title":"Recombinant growth hormone for idiopathic short stature in children and adolescents","author":"Bryant","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071616571328800_B27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/EJE-09-0880","article-title":"High dose hGH treatment limited to the prepubertal period in young children with ISS does not increase adult height.","volume":"162","author":"van Gool","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2020071616571328800_B28","first-page":"277","article-title":"Psychosocial functioning, self-perception and body image and their auxological correlates in GH and oestrogen-treated young adult women with Turner syndrome.","volume":"66","author":"Lagrou","year":"2006","journal-title":"Horm Res"},{"key":"2020071616571328800_B29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1651-2227.2007.00235.x","article-title":"Long-term psychosocial consequences of hormone treatment for short stature.","volume":"96","author":"Visser-van Balen","year":"2007","journal-title":"Acta Paediatrica"},{"key":"2020071616571328800_B30","unstructured":"Office for Human Research Protections (OHRP) 2004 Belmont report. Ethical principles and guidelines for the protection of human subjects of research. U.S. Department of Health and Human Services. http:\/\/www.hhs.gov\/ohrp\/archive\/belmontArchive.html"},{"key":"2020071616571328800_B31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1542\/peds.2006-0329","article-title":"Growth hormone therapy for short stature: is the benefit worth the burden.","volume":"118","author":"Allen","year":"2006","journal-title":"Pediatrics"},{"key":"2020071616571328800_B32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant growth hormone in children.","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B33","doi-asserted-by":"crossref","first-page":"E1025","DOI":"10.1210\/jc.2010-3023","article-title":"Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research study.","volume":"96","author":"Child","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616571328800_B34","unstructured":"U.S. Food and Drug Administration 22 December 2010 Alert: recombinant human growth hormone (somatropin): ongoing safety review\u2014possible increased risk of death. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm237969.htm"},{"key":"2020071616571328800_B35","article-title":"Are children dying for an inch or two? The ethics and dangers of treating children with growth-boosting drugs","author":"Dreger","year":"2001","journal-title":"Chicago Tribune"},{"key":"2020071616571328800_B36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jpeds.2010.10.004","article-title":"Pediatric endo-cosmetology and the evolution of growth diagnosis and treatment.","volume":"158","author":"Rosenbloom","year":"2011","journal-title":"J Pediatr"},{"key":"2020071616571328800_B37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1353\/pbm.1990.0052","article-title":"Is taller really better? Growth hormone therapy in short children.","volume":"34","author":"Diekema","year":"1990","journal-title":"Perspect Biol Med"},{"key":"2020071616571328800_B38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1542\/peds.2008-0712","article-title":"Childhood obesity and medical neglect.","volume":"123","author":"Varness","year":"2009","journal-title":"Pediatrics"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/10\/3042\/9110317\/jcem3042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/10\/3042\/9110317\/jcem3042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T23:56:32Z","timestamp":1686268592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/10\/3042\/2834864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-1739","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}